266 related articles for article (PubMed ID: 19749488)
1. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
[No Abstract] [Full Text] [Related]
2. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
3. A review of minodronic acid hydrate for the treatment of osteoporosis.
Tanishima S; Morio Y
Clin Interv Aging; 2013; 8():185-9. PubMed ID: 23440003
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
5. [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Chatani Y
Clin Calcium; 2005 Jan; 15(1):9-14. PubMed ID: 15632466
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].
Shiraishi A
Nihon Yakurigaku Zasshi; 2014 Jun; 143(6):302-9. PubMed ID: 24919557
[No Abstract] [Full Text] [Related]
7. [When should bisphosphonate treatment be discontinued?].
Eriksen EF; Halse J
Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
[No Abstract] [Full Text] [Related]
8. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study.
Tanaka S; Yoshida A; Kono S; Ito M
J Orthop Sci; 2017 May; 22(3):536-541. PubMed ID: 28108224
[TBL] [Abstract][Full Text] [Related]
9. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
10. [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
Tomoo T; Suzuki M
Nihon Yakurigaku Zasshi; 2005 Nov; 126(5):353-7. PubMed ID: 16394581
[No Abstract] [Full Text] [Related]
11. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
Takata S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Sakurai T
Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs.
Martín-Jiménez T; De Lorimier LP; Fan TM; Freise KJ
J Vet Pharmacol Ther; 2007 Oct; 30(5):492-5. PubMed ID: 17803746
[No Abstract] [Full Text] [Related]
15. Bisphosphonates: how do they work?
Papapoulos SE
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
[TBL] [Abstract][Full Text] [Related]
16. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
Voskaridou E; Christoulas D; Antoniadou L; Terpos E
Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
[No Abstract] [Full Text] [Related]
17. Bisphosphonates for osteoporosis--where do we go from here?
Whitaker M; Guo J; Kehoe T; Benson G
N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
[No Abstract] [Full Text] [Related]
18. Minodronate for the treatment of osteoporosis.
Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
[TBL] [Abstract][Full Text] [Related]
19. Fracture risk and zoledronic acid therapy in men with osteoporosis.
Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
[TBL] [Abstract][Full Text] [Related]
20. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
Ikeda K; Fukagawa M
Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
